Skip to main content
SpringerLink
Log in
Book cover

Tumor Models in Cancer Research pp 565–589Cite as

Spontaneous Pet Animal Cancers

  • Chapter

  • 436 Accesses

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

A significant amount of the in vivo work assessing cancer biology or experimental therapeutics is conducted in small laboratory animals. Indeed, the vast majority of this book is based on in vivo laboratory animal systems that have enabled significant advances to be made in the understanding of cancer. Clearly, there are many advantages associated with these models. Alternatively, however, studies of spontaneous cancer can provide information that cannot be obtained elsewhere, except for the study of cancer in humans. Spontaneous tumors in large animals (dogs and cats) can provide a bridge between novel discoveries in the laboratory and implementation of new therapies in humans in a number of novel ways. This chapter reviews some of the basic aspects of spontaneous large animal tumors and provides specific examples of results that have important implications for human cancer therapy.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dorn C,Taylor D, Schneider R, Hibbard H, Klauber M. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda county. J Natl Cancer Inst 1968; 40:307–318.

    Google Scholar 

  2. Greenle R, Murray T, Bolden S, Wingo P. Cancer Statistics, 2000. CA Cancer J Clin 2000; 50: 7–33.

    Article  Google Scholar 

  3. Hardy Jr. W, Hess P, MacEwen E, McClelland A, Zuckerman E, Essex M, et al. Biology of feline leukemia virus in the natural environment. Cancer Res 1976; 36: 582–588.

    PubMed  Google Scholar 

  4. Shelton G, Grant C, Cotter S, Gardner M, Hardy Jr. W, DiGiacomo R. Feline immunodeficiency virus and feline leukemia virus infections and their relationships to lymphoid malignancies in cats: a retrospective study (1968–1988). J Acquir Immune Defic Syndr 1990; 3: 623–630.

    Google Scholar 

  5. Essex M, Klein G, Snyder S, Harrold J. Correlation between humoral antibody and regression of tumours induced by feline sarcoma virus. Nature 1971; 233: 195–196.

    Article  PubMed  CAS  Google Scholar 

  6. Hendrick M, Goldschmidt M, Shofer F, Wang Y, Somlyo A. Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identification of aluminum. Cancer Res 1992; 52: 5391–5394.

    PubMed  CAS  Google Scholar 

  7. Glickman L, Domanski L, Maguire T, Dubielzig R, Churg A. Mesothelioma in pet dogs associated with exposure of their owners to asbestos. Environ Res 1983; 32: 305–313.

    Article  PubMed  CAS  Google Scholar 

  8. Hayes Jr. H, Hoover R, Tarone R. Bladder cancer in pet dogs: a sentinel for environmental cancer? J Epidemiol 1981; 114: 229–233.

    Google Scholar 

  9. Reif J, Cohen D. The environmental distribution of canine respiratory tract neoplasms. Arch Environ Health 1971; 22: 136–140.

    PubMed  CAS  Google Scholar 

  10. Patronek G, Rowan A. Editorial-Determining dog and cat numbers and population dynamics. Anthrozoos 1995; 8: 199–205.

    Article  Google Scholar 

  11. Puccio M, Nathanson L. The cancer cachexia syndrome. Semin Oncol 1997; 24: 277–287.

    PubMed  CAS  Google Scholar 

  12. Trott K-R. Differences between mouse and human tumors that affect their responses to radiotherapy. In: Kallman R, ed. Rodent Tumor Models in Experimental Cancer Therapy. Pergamon Press, New York, NY, 1987. pp. 6–11.

    Google Scholar 

  13. Hall E. Cell, Tissue, and Tumor Kinetics. In: Hall E, ed. Radiobiology for the Radiologist. 4th ed. J.B. Lippincott Philadelphia, PA, 1994. pp. 191–210.

    Google Scholar 

  14. Steel G. Growth Kinetics of Tumours. Oxford University Press, Oxford, 1977.

    Google Scholar 

  15. Larne SM, Fox MH, Ogilvie GK, Page RL, Getzy DM, Thrall DE, et al. Tumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy alone or combined with whole body hyperthermia. Int J Hyperthermia 1999; 15 (6): 475–486.

    Article  Google Scholar 

  16. Vail DM, Kisseberth WC, Obradovich JE, Moore FM, London CA, MacEwen EG, et al. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin’s lymphoma [see comments]. Exp Hematol 1996; 24 (7): 807–815.

    PubMed  CAS  Google Scholar 

  17. LaRue SM, Fox MH, Withrow SJ, Powers BE, Straw RC, Cote IM, et al. Impact of heterogeneity in the predictive value of kinetic parameters in canine osteosarcoma. Cancer Res 1994; 54 (14): 3916–3921.

    PubMed  CAS  Google Scholar 

  18. Schwyn U, Crompton NE, Blattmann H, Hauser B, Klink B, Parvis A, et al. Potential tumour doubling time: determination of Tpot for various canine and feline tumours. Vet Res Commun 1998; 22 (4): 233–247.

    Article  PubMed  CAS  Google Scholar 

  19. MacEwen EG. An immunologic approach to the treatment of cancer. Vet Clin North Am 1977; 7 (1): 65–75.

    PubMed  CAS  Google Scholar 

  20. MacEwen EG. Approaches to cancer therapy using biological response modifiers. Vet Clin North Am SmallAnim Pract 1985; 15 (3): 667–688.

    CAS  Google Scholar 

  21. MacEwen EG, Kurzman ID. Canine osteosarcoma: amputation and chemoimmunotherapy. Vet Clin N Am SmallAnim Pract 1996; 26 (1): 123–133.

    CAS  Google Scholar 

  22. MacEwen EG, Kurzman ID, Vail DM, Dubielzig RR, Everlith K, Madewell BR, et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999; 5 (12): 4249–4258.

    PubMed  CAS  Google Scholar 

  23. Crompton N, Ozsahin M, Schweizer P, Larsson B, Luetolf U. Theory and practice of predictive assays in radiation therapy. Strahlenther Onkol 1997; 173: 58–67.

    Article  PubMed  CAS  Google Scholar 

  24. Hall P, Going J. Predicting the future: a critical appraisal of cancer prognosis studies. Histopathology 1999; 6: 489–494.

    Article  Google Scholar 

  25. Dewhirst MW, Sim DA. The utility of thermal dose as a predictor of tumor and normal tissue responses to combined radiation and hyperthermia. Cancer Res 1984; 44 (10 Suppl): 4772s - 4780s.

    PubMed  CAS  Google Scholar 

  26. Dewhirst MW, Sim DA. Estimation of therapeutic gain in clinical trials involving hyperthermia and radiotherapy. Int J Hyperthermia 1986; 2: 165–178.

    Article  PubMed  CAS  Google Scholar 

  27. McChesney-Gillette S, Dewhirst MW, Gillette EL, Thrall DE, Page RL, Powers BE, et al. Response of canine soft tissue sarcomas to radiation or radiation plus hyperthermia: a randomized phase II study. Int J Hyperthermia 1992; 8: 309–320.

    Article  Google Scholar 

  28. Gillette EL, McChesney SL, Dewhirst MW, Scott RJ. Response of canine oral carcinomas to heat and radiation. Intl Radiat Oncol Biol Phys 1987; 13 (12): 1861–1867.

    Article  CAS  Google Scholar 

  29. Denman DL, Legorreta RA, Kier AB, Elson HR, White ML, Buncher CR, et al. Therapeutic responses of spontaneous canine malignancies to combinations of radiotherapy and hyperthermia. Int J Radiat Oncol Biol Phys 1991; 21(2):415–422.

    Google Scholar 

  30. Dewhirst MW, Sim DA, Wilson S, DeYoung D, Parsells JL. The correlation between initial and longterm responses in pet animal tumors to heat and radiation or radiation alone. Cancer Res 1983; 43: 5735–5741.

    PubMed  CAS  Google Scholar 

  31. van der Zee J, Gonzalez Gonzalez D, van Rhoon G, van Dijk J, van Putten W, Hart A. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Lancet 2000; 355: 1119–1125.

    Article  PubMed  Google Scholar 

  32. Vernon C, Hand J, Field S, Machin D, Whaley J, van der Zee J, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized brest cancer: results from five randomized controlled trials. Int J Radiat Oncol Biol Phys 1996; 35: 731–744.

    Article  PubMed  CAS  Google Scholar 

  33. Valdagni R, Amichetti M. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. Int J Radiat Oncol Biol Phys 1994; 28 (1): 163–169.

    Article  PubMed  CAS  Google Scholar 

  34. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Melia O, et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 1996; 12 (1): 3–20.

    Article  PubMed  CAS  Google Scholar 

  35. Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998; 40(2):287–295.

    Google Scholar 

  36. McChesney S, Gillette E, Dewhirst M, Withrow S. Influence of WR 2721 on radiation response of canine soft tissue sarcomas. Ina.1 Radiat Oncol Biol Phys 1986; 12: 1957–1963.

    Article  CAS  Google Scholar 

  37. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998; 4 (6): 1567–1571.

    PubMed  CAS  Google Scholar 

  38. Kurzman ID, MacEwen EG, Rosenthal RC, Fox LE, Keller ET, Helfand SC, et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1995; 1 (12): 1595–601.

    PubMed  CAS  Google Scholar 

  39. Page R, Thrall D, Dewhirst M, Macy D, George S, McEntee M, et al. Phase I study of melphalan alone and melphalan plus whole body hypertherma in dogs withmalignant melanoma. Int J Hyperthermia 1991; 7: 559–566.

    Article  PubMed  CAS  Google Scholar 

  40. Page R, Thrall D, George S, Price G, Heidner G, McEntee M, et al. Quantitative estimation of the thermal dose-modifying factor for cis-diamminedichloroplatinum (CDDP) in tumour-bearing dogs. Int J Hyperthermia 1992; 8: 761–769.

    Article  PubMed  CAS  Google Scholar 

  41. Page R, Macy D, Ogilvie G, Rosner G, Dewhirst M, Thrall D, et al. Phase III evaluation of doxorubicin and whole body hyperthermia in dogs with lymphoma. Ina J Hyperthermia 1992; 8: 187–197.

    Article  CAS  Google Scholar 

  42. Page R, McEntee M, Williams P, George S, Price G, Novotney C, et al. Effect of whole body hyperthermia on carboplatin disposition and toxicity in dogs. Int J Hyperthermia 1994; 10: 807–816.

    Article  PubMed  CAS  Google Scholar 

  43. Cline JM, Rosner GL, Raleigh JA, Thrall DE. Quantification of CCI-103F labeling heterogeneity in canine solid tumors. Inn J Radiat Oncol Biol Phys 1997; 37 (3): 655–662.

    Article  CAS  Google Scholar 

  44. Thrall DE, McEntee MC, Cline JM, Raleigh JA. ELISA quantification of CCI-103F in canine tumors prior to and during irradiation. Int J Radiat Oncol Biol Phys 1994; 28: 649–659.

    Article  PubMed  CAS  Google Scholar 

  45. Thrall DE, Prescott DM, Samulski TV, Rosner GL, Denman DL, Legorreta RL, et al. Radiation plus local hyperthermia versus radiation plus the combination of local and whole-body hyperthermia in canine sarcomas. Im’ J Radiat Oncol Biol Phys 1996; 34 (5): 1087–1096.

    Article  CAS  Google Scholar 

  46. Champ C, Tyler X, Andrews P, Coghill S. Improve your hospital autopsy rate to 40–50 per cent, a tale of two towns. J Pathol 1992; 166: 405–407.

    Article  PubMed  CAS  Google Scholar 

  47. Organization WH. TNM Classification of tumors in domestic animals. Geneva: World Health Organization; 1980.

    Google Scholar 

  48. MacEwen EG. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 1990; 9 (2): 125–136.

    Article  PubMed  CAS  Google Scholar 

  49. Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop 1991(270):159–168.

    Google Scholar 

  50. Vail DM, MacEwen E. Spontaneous occurring tumors of companion animals as models for human cancer. Cancer Invest 2000; 18: 767–778.

    Article  Google Scholar 

  51. Gilbertson SR, Kurzman ID, Zachrau RE, Hurvitz AI, Black MM. Canine mammary epithelial neoplasms: biologic implications of morphologic characteristics assessed in 232 dogs. Vet Pathol 1983; 20 (2): 127–142.

    PubMed  CAS  Google Scholar 

  52. Conroy JD. Melanocytic tumors of domestic animals with special reference to dogs. Arch Dermatol 1967; 96 (4): 372–380.

    Article  PubMed  CAS  Google Scholar 

  53. Cooley DM, Waters DJ. Skeletal metastasis as the initial clinical manifestation of metastatic carcinoma in 19 dogs. J Vet Intern Med 1998; 12 (4): 288–293.

    Article  PubMed  CAS  Google Scholar 

  54. Brodey RS. The use of naturally occurring cancer in domestic animals for research into human cancer: general considerations and a review of canine skeletal osteosarcoma. Yale J Biol Med 1979; 52 (4): 345–361.

    PubMed  CAS  Google Scholar 

  55. Brodey RS, Riser WH. Canine osteosarcoma. A clinicopathologic study of 194 cases. Clin Orthop 1969; 62: 54–64.

    PubMed  CAS  Google Scholar 

  56. Bostock DE. Prognosis after surgical excision of canine melanomas. Vet Pathol 1979; 16 (1): 32–40.

    PubMed  CAS  Google Scholar 

  57. Brown NO, Patnaik AK, MacEwen EG. Canine hemangiosarcoma: retrospective analysis of 104 cases. JAm Vet Med Assoc 1985; 186 (1): 56–58.

    CAS  Google Scholar 

  58. MacEwen EG, Hayes AA, Harvey HJ, Patnaik AK, Mooney S, Passe S. Prognostic factors for feline mammary tumors. JAm Vet Med Assoc 1984; 185 (2): 201–204.

    CAS  Google Scholar 

  59. Misdorp W, Romijn A, Hart AA. Feline mammary tumors: a case-control study of hormonal factors. Anticancer Res 1991; 11 (5): 1793–1797.

    PubMed  CAS  Google Scholar 

  60. Scavelli TD, Patnaik AK, Mehlhaff CJ, Hayes AA. Hemangiosarcoma in the cat: retrospective evaluation of 31 surgical cases. JAm Vet Med Assoc 1985; 187 (8): 817–819.

    CAS  Google Scholar 

  61. Weijer K, Hart AA. Prognostic factors in feline mammary carcinoma. J Natl Cancer Inst 1983; 70 (4): 709–716.

    PubMed  CAS  Google Scholar 

  62. Benjamin SA, Lee AC, Saunders WJ. Classification and behavior of canine mammary epithelial neoplasms based on life-span observations in beagles. Vet Pathol 1999; 36 (5): 423–436.

    Article  PubMed  CAS  Google Scholar 

  63. Kurzman ID, Gilbertson SR. Prognostic factors in canine mammary tumors. Semin Vet Med Surg (Small Anim) 1986; 1: 25–32.

    CAS  Google Scholar 

  64. Kuntz CA, Dernell WS, Powers BE, Devitt C, Straw RC, Withrow SJ. Prognostic factors for surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986–1996). J Am Vet Med Assoc 1997; 211 (9): 1147–1151.

    PubMed  CAS  Google Scholar 

  65. Bostock DE. The prognosis following the surgical excision of canine mammary neoplasms. Eur J Cancer 1975; 11 (6): 389–396.

    PubMed  CAS  Google Scholar 

  66. Vail DM, Powers BE, Getzy DM, Morrison WB, McEntee MC, O’Keefe DA, et al. Evaluation of prognostic factors for dogs with synovial sarcoma: 36 cases (1986–1991). JAm Vet Med Assoc 1994; 205 (9): 1300–1307.

    CAS  Google Scholar 

  67. Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993; 7 (5): 289–9.

    Article  PubMed  CAS  Google Scholar 

  68. Teska E, van Heerde P, Rutterman G. Prognostic factors for treatment of malignant lymphoma in dogs. JAm Vet Med Assoc 1994; 205: 1722–1728.

    Google Scholar 

  69. Greenlee PG, Filippa DA, Quimby FW, Patnaik AK, Calvano SE, Matus RE, et al. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 1990; 66 (3): 480–490.

    Article  PubMed  CAS  Google Scholar 

  70. Vail DM, Moore AS, Ogilvie GK, Volk LM. Feline lymphoma (145 cases): proliferation indices, cluster of differentiation 3 immunoreactivity, and their association with prognosis in 90 cats. J Vet Intern Med 1998; 12 (5): 349–354.

    Article  PubMed  CAS  Google Scholar 

  71. Cuoto C. Clinicopathologic aspects of acute leukemias in the dog. J Am Vet Med Assoc 1985; 186: 681–685.

    Google Scholar 

  72. Leifer C, Matus RE, Saal S, MacEwen E. Chronic myelogenous leukemia in the dog. J Am Vet Med Assoc 1983; 183: 686–689.

    PubMed  CAS  Google Scholar 

  73. Matus RE, Leifer C, MacEwen E. Acute lymphoblastic leukemia in the dog: a review of 30 cases. J Am Vet Med Assoc 1983; 183: 859–862.

    PubMed  CAS  Google Scholar 

  74. Matus RE, Leifer C, MacEwen E, Hurvitz AI. Prognostic factors for multiple myeloma in the dog. J Am Vet Med Assoc 1986; 188: 1288–1292.

    PubMed  CAS  Google Scholar 

  75. Leifer C, Matus RE. Chronic lymphocytic leukemia in the dog: 22 cases. JAm Vet Med Assoc 1986; 189: 214–217.

    CAS  Google Scholar 

  76. Benchimol S, Minden M. Viruses, oncogenes and tumor suppressor genes. In: Tannock I, Hill RP, eds. The Basic Science of Oncology, 3rd ed. McGraw Hill Co., New York, 1998, pp. 79–105.

    Google Scholar 

  77. Krontiris TG. Oncogenes. N Engl J Med 1995; 333 (5): 303–306.

    Article  PubMed  CAS  Google Scholar 

  78. Smith ML, Fornace AJ, Jr. The two faces of tumor suppressor p53. Am J Pathol 1996; 148 (4): 1019–1022.

    PubMed  CAS  Google Scholar 

  79. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266 (5186): 807–810.

    Article  PubMed  CAS  Google Scholar 

  80. van Leeuwen I, Hellman E, Cornelisse C, van den Burgh B, Rutterman G. p53 mutations in mammary tumor cell lines and corresponding tumor tissue in the dog. Anticancer Res 1996; 16: 3737–3744.

    PubMed  Google Scholar 

  81. Chu L, Rutterman G, Kong J, Ghahremani M, Schmeing M, Misdorp W, et al. Genomic organization of the canine p53 gene and its mutation status in canine mammary neoplasia. Breast Cancer Res Treat 1998; 50: 11–25.

    Article  PubMed  CAS  Google Scholar 

  82. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253 (5015): 49–53.

    Article  PubMed  CAS  Google Scholar 

  83. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54 (18): 4855–4878.

    PubMed  CAS  Google Scholar 

  84. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996; 13 (9): 1971–1981.

    PubMed  CAS  Google Scholar 

  85. van Leeuwen I, Cornelisse C, Misdorp W, Goedegebuure S, Kirpenstein J, Rutterman G. p53 gene mutations in osteosarcomas in the dog. Cancer Let 1997; 111: 173–178.

    Article  Google Scholar 

  86. Veldhoen N, Stewart J, Brown R, Milner J. Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog. Oncogene 1998; 16 (2): 249–255.

    Article  PubMed  CAS  Google Scholar 

  87. Gamblin RM, Sagartz JE, Couto CG. Overexpression of p53 tumor suppressor protein in spontaneously arising neoplasms of dogs. Am J Vet Res 1997; 58 (8): 857–863.

    PubMed  CAS  Google Scholar 

  88. Mendoza S, Konishi T, Derrell WS, Withrow SJ, Miller CW. Status of the p53, Rb and MDM2 genes in canine osteosarcoma. Anticancer Res 1998; 18 (6A): 4449–4453.

    PubMed  CAS  Google Scholar 

  89. Mayr B, Schaffner G, Kurzbauer R. Mutations in tumor suppressor gene p53 in two feline fibrosarcomas. Br Vet J 1995; 151: 707–713.

    Article  PubMed  CAS  Google Scholar 

  90. Hannink M, Donoghue DJ. Structure and function of platelet-derived growth factor (PDGF) and related proteins. Biochim Biophys Acta 1989; 989 (l): 1–10.

    PubMed  CAS  Google Scholar 

  91. Leveen P, Claesson-Welsh L, Heldin CH, Westermark B, Betsholtz C. Expression of messenger RNAs for platelet-derived growth factor and its receptors in human sarcoma cell lines. Int J Cancer 1990; 46 (6): 1066–1070.

    Article  PubMed  CAS  Google Scholar 

  92. Liang Y, Robinson DF, Dennig J, Suske G, Fahl WE. Transcriptional regulation of the SIS/PDGF-B gene in human osteosarcoma cells by the Sp family of transcription factors. J Biol Chem 1996; 271 (20): 11, 792–11, 797.

    Google Scholar 

  93. Yang D, Kohler SK, Maher VM, McCormick JJ. v-sis oncogene-induced transformation of human fibroblasts into cells capable of forming benign tumors. Carcinogenesis 1994; 15 (10): 2167–2175.

    Article  PubMed  CAS  Google Scholar 

  94. Ahern T, Bird C, Bird A, Wolfe L. Overexpression of c-erbB-2 and c-myc but not c-ras, in canine melanoma cell lines is associated with metastatic potential in nude mice. Anticancer Res 1996; 13: 1365–1371.

    Google Scholar 

  95. Ahern T, Bird A, Bird R, Wolfe L. Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived lines. Am J Vet Res 1996; 57: 693–696.

    PubMed  CAS  Google Scholar 

  96. Inoue M, Wada N. Immunohistochemical detection of p53 and p21 proteins in canine testicular tumours. Vet Rec 2000; 146 (13): 370–372.

    Article  PubMed  CAS  Google Scholar 

  97. Inoue M, Shiramizu K. Immunohistochemical detection of p53 and c-myc proteins in canine mammary tumours. J Comp Pathol 1999; 120 (2): 169–175.

    Article  PubMed  CAS  Google Scholar 

  98. Forrest D, Onioris D, Lees G, Neil JC. Altered structure and expression of c-myc in feline T-cell tumours. Virology 1987; 158 (1): 194–205.

    Article  PubMed  CAS  Google Scholar 

  99. Mellon K, Wright C, Kelly P, Home CH, Neal DE. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 1995; 153 (3 Pt 2): 919–925.

    PubMed  CAS  Google Scholar 

  100. Neal DE, Marsh C, Bennett MK, Abel PD, Hall RR, Sainsbury JR, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985; 1 (8425): 366–368.

    Article  PubMed  CAS  Google Scholar 

  101. Porter-Jordan K, Lippman ME. Overview of the biologic markers of breast cancer. Hematol Oncol Clin NAm 1994; 8 (1): 73–100.

    CAS  Google Scholar 

  102. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999; 10 (Suppl. 4): 145–149.

    Article  PubMed  Google Scholar 

  103. Rutterman GR, Foekens JA, Portengen H, Vos JH, Blankenstein MA, Teske E, et al. Expression of epidermal growth factor receptor (EGFR) in non-affected and tumorous mammary tissue of female dogs. Breast Cancer Res Treat 1994; 30 (2): 139–146.

    Article  Google Scholar 

  104. MacEwen E, Pastor J, Kutze J, Tsan R, Kurzman ID, Wilson M, et al. Insulin-like growth factor-1 (IGF-1) and IGF-1 receptor expression contributes to the malignant phenotype in osteosarcoma. Cancer Res 2000;Submitted.

    Google Scholar 

  105. MacEwen E, Kutze J, Carew J, Pastor J, Tsan R, Radinsky R. c-met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Cancer Res 2000; submitted.

    Google Scholar 

  106. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein famesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999; 17 (11): 3631–3652.

    PubMed  CAS  Google Scholar 

  107. Minamoto T, Mai M, Ronai Z. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers-a review. Cancer Detect Prey 2000; 24 (1): 1–12.

    CAS  Google Scholar 

  108. Castagnaro M. Ras gene analysis in mammary tumors of dogs by means of PCR-SSCP and direct genomic analysis. Anneli dell Instituto Superiore di Sanita 1995; 31: 337–341.

    CAS  Google Scholar 

  109. Kraegel S, Gumerlock P, Dungworth D, Oreffo V, Madewell BR. K-ras activation in non-small cell lung cancer in the dog. Cancer Res 1992; 52: 4724–4727.

    PubMed  CAS  Google Scholar 

  110. Steingold S, Sharp N, McGahan M, Hughes C, Dunn S, Page RL. Characterization of canine MDR1 mRNA: its abundance in drug resistant cell lines and in vivo. Anticancer Res 1998; 18: 393–400.

    PubMed  CAS  Google Scholar 

  111. Lee J, Hughes C, Fine R, Page RL. P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer 1996; 77: 1892–1898.

    Article  PubMed  CAS  Google Scholar 

  112. Moore AS, Leveille C, Reimann K, Shu H, Arias I. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Invest 1995; 13: 475–479.

    Article  PubMed  CAS  Google Scholar 

  113. Straw RC. Tumors of the skeletal system. In: Withrow SJ, ed. Small Animal Clinical Oncology, 2nd ed. WB Saunders, Philadelphia, PA, 1996, pp. 1509–1566.

    Google Scholar 

  114. Bergman PJ, MacEwen EG, Kurzman ID, Henry CJ, Hammer AS, Knapp DW, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996; 10 (2): 76–81.

    Article  PubMed  CAS  Google Scholar 

  115. Mauldin GN, Matus RE, Withrow SJ, Patnaik AK. Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 1988; 2 (4): 177–180.

    Article  PubMed  CAS  Google Scholar 

  116. Berg J, Weinstein MJ, Springfield DS, Rand WM. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. JAm Vet Med Assoc 1995; 206 (10): 1555–1560.

    CAS  Google Scholar 

  117. Chun R, Kurzman ID, Cuoto G, Klausne J, Henry C, MacEwen E. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. J Vet Int Med 2000; 14: 495–498.

    Article  CAS  Google Scholar 

  118. Berg J, Gebhardt MC, Rand WM. Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997; 79 (7): 1343–1350.

    Article  PubMed  CAS  Google Scholar 

  119. Derrell WS, Withrow SJ, Straw RC, Powers BE, Drekke JH, Lafferty M. Intracavitary treatment of soft tissue sarcomas in dogs using cisplatin in a biodegradable polymer. Anticancer Res 1997; 17 (6D): 4499–4505.

    Google Scholar 

  120. Withrow SJ, Straw RC, Brekke J. Slow release adjuvant cisplatin for the treatment of metastatic canine osteosarcoma. Eur J Musculoskeletal Res 1995; 4: 105–110.

    CAS  Google Scholar 

  121. Vail DM, Kravis LD, Cooley AJ, Chun R, MacEwen EG. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol 1997; 39 (5): 410–416.

    Article  PubMed  CAS  Google Scholar 

  122. Thamm DH, Vail DM. Preclinical evaluation of a sterically stabilized liposome-encapsulated cisplatin in clinically normal cats. Am J Vet Res 1998; 59 (3): 286–289.

    PubMed  CAS  Google Scholar 

  123. Hershey AE, Kurzman ID, Forrest LJ, Bohling CA, Stonerook M, Placke ME, et al. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res 1999; 5 (9): 2653–2659.

    PubMed  CAS  Google Scholar 

  124. Bostock DE, Gorman NT. Intravenous BCG therapy of mammary carcinoma in bitches after surgical excision of the primary tumour. Eur J Cancer 1978; 14 (8): 879–883.

    PubMed  CAS  Google Scholar 

  125. Fox LE, MacEwen E, Kurzman ID. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma-a multicenter randomized double blind study. Cancer Biotherapy 1995; 10: 125–130.

    Article  PubMed  CAS  Google Scholar 

  126. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Keller ET, et al. Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. Hum Gene Ther 1998; 9 (13): 1851–1861.

    Article  PubMed  CAS  Google Scholar 

  127. MacEwen EG, Harvey Hi, Patnaik AK, Mooney S, Hayes A, Kurzman I, et al. Evaluation of effects of levamisole and surgery on canine mammary cancer. J Biol Response Mod 1985; 4 (4): 418–426.

    PubMed  CAS  Google Scholar 

  128. Teske E, Rutteman GR, v.d. Ingh TS, van Noort R, Misdorp W. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma. Anticancer Res 1998; 18 (2A): 1015–1019.

    PubMed  CAS  Google Scholar 

  129. Vail DM, MacEwen E, Kurzman I, Dubielzig RR, Helfand SC, Kisseberth WC, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res 1995; 1: 1165–1170.

    PubMed  CAS  Google Scholar 

  130. MacEwen EG, Hayes AA, Mooney S, Patnaik AK, Harvey HJ, Passe S, et al. Evaluation of effect of levamisole on feline mammary cancer. J Biol Response Mod 1984; 3(5):541–546.

    Google Scholar 

  131. MacEwen EG, Kurzman ID, Rosenthal RC, Smith BW, Manley PA, Roush JK, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Nail Cancerinst 1989; 81 (12): 935–938.

    Article  CAS  Google Scholar 

  132. Fidler IJ, Sone S, Fogler WE, Barnes ZL. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 1981; 78 (3): 1680–1684.

    Article  PubMed  CAS  Google Scholar 

  133. Fidler IJ. Therapy of cancer metastasis by systemic activation of macrophages. Adv Pharmacol 1994; 30: 271–326.

    Article  PubMed  CAS  Google Scholar 

  134. Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 1995; 18 (2): 93–99.

    Article  PubMed  CAS  Google Scholar 

  135. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Yang NS, et al. Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Cancer Gene Ther 1999; 6 (1): 26–36.

    Article  PubMed  CAS  Google Scholar 

  136. Novotney C, Page R, Macy D, Dewhirst M, Ogilvie G, Withrow S, et al. Phase I evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphoma. J Vet Int Med 1992; 6: 245–249.

    Article  CAS  Google Scholar 

  137. Hauck M, Price G, Ogilvie G, Johnson J, Gillette E, Thrall D, et al. Phase I evaluation of mitoxantrone alone and combined with whole body hyhperthermia in dogs with lymphoma. Int J Hyperthermia 1995; 12: 309–320.

    Article  Google Scholar 

  138. Page RL, Lee J, Riviere JE, Dodge RK, Thrall DE, Dewhirst MW. Absence of whole body hyperthermia effect on cisplatin distribution in spontaneous canine tumors. Int J Radiat Oncol Biol Phys 1995; 32 (4): 1097–102.

    Article  PubMed  CAS  Google Scholar 

  139. McChesney SL, Withrow SJ, Gillette EL, Powers BE, Dewhirst MW. Radiotherapy of soft tissue sarcomas in dogs. JAm Vet Med Assoc 1989; 194 (1): 60–63.

    CAS  Google Scholar 

  140. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Melia O, et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology [see comments]. Lancet 1995; 345 (8949): 540–543.

    Article  PubMed  CAS  Google Scholar 

  141. Dewhirst MW, Winget JM, Edelstein-Keshet L, Sylvester J, Engler M, Thrall DE, et al. Clinical application of thermal isoeffect dose. Int J Hyperthermia 1987; 3 (4): 307–318.

    Article  PubMed  CAS  Google Scholar 

  142. Valdagni R, Liu FF, Kapp DS. Important prognostic factors influencing outcome of combined radiation and hyperthermia. Int J Radiat Oncol Biol Phys 1988; 15 (4): 959–972.

    Article  PubMed  CAS  Google Scholar 

  143. Kapp DS, Cox RS. Thermal treatment parameters are most predictive of outcome in patients with single tumor nodules per treatment field in recurrent adenocarcinoma of the breast [see comments]. Int J Radiat Oncol Biol Phys 1995; 33 (4): 887–899.

    Article  PubMed  CAS  Google Scholar 

  144. Oleson J, Samulski T, Leopold K, Clegg S, Dewhirst M, Dodge R, et al. Sensitivity of hyperthermia trial outcomes to temperature and time: implications for thermal goals of treatment. Int J Radiat Oncol Biol Phys 1993; 25: 289–297.

    Article  PubMed  CAS  Google Scholar 

  145. Seegenschmiedt MH, Martus P, Fietkau R, Iro H, Brady LW, Sauer R. Multivariate analysis of prognostic parameters using interstitial thermoradiotherapy (IHT-IRT): tumor and treatment variables predict outcome. Int J Radiat Oncol Biol Phys 1994; 29 (5): 1049–1063.

    Article  PubMed  CAS  Google Scholar 

  146. Dewhirst M. Thermal Dosimetry. In: Seegenschmiedt M, Fessenden P, Vernon C, eds. Thermo-radiotherapy and thermochemotherapy. Springer-Verlag, Berlin, 1995, pp. 123–136.

    Chapter  Google Scholar 

  147. Thrall D, Rosner G, Azuma C, LaRue S, Case B, Samulski T, et al. Using units of CEM 43•C T90, local hyperthermia thermal dose can be delivered as prescribed. Int J Hyperthermia 2000; 16: 415–428.

    Article  PubMed  CAS  Google Scholar 

  148. Thrall D, LaRue S, Powers B, Page R, Johnson J, George S, et al. Use of whole body hyperthermia as a method to heat inaccessible tumours uniformly: a phase III trial in canine brain masses. Int J Hyperthermia 1999; 15: 383–398.

    Article  PubMed  CAS  Google Scholar 

  149. Thrall D, Withrow S, Powers B, Straw R, Page R, Heidner G, et al. Radiotherapy prior to cortical allograft limb sparing in dogs with osteosarcoma: a dose response assay. Int J Radiat Oncol Biol Phys 1990; 18: 1351–1357.

    Article  PubMed  CAS  Google Scholar 

  150. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38 (2): 285–289.

    Article  PubMed  CAS  Google Scholar 

  151. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999; 53 (2): 113–117.

    Article  PubMed  CAS  Google Scholar 

  152. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41: 31–39.

    PubMed  CAS  Google Scholar 

  153. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56 (19): 4509–4515.

    PubMed  CAS  Google Scholar 

  154. Hockel M, Schlenger K, Hockel S, Aral B, Schaffer U, Vaupel P. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer 1998; 79 (4): 365–369.

    Article  PubMed  CAS  Google Scholar 

  155. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer [published erratum appears in Radiother Oncol 1999 Mar;50(3):371]. Radiother Oncol 1998; 48 (2): 149–156.

    Article  PubMed  CAS  Google Scholar 

  156. Rofstad EK, Sundfor K, Lyng H, Trope CG. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000; 83 (3): 354–359.

    Article  PubMed  CAS  Google Scholar 

  157. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56 (5): 941–943.

    PubMed  CAS  Google Scholar 

  158. Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB, Fowler WC, Jr., et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 1998; 71 (2): 270–277.

    Article  PubMed  CAS  Google Scholar 

  159. Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res 1996; 56(2):405–411.

    Google Scholar 

  160. Evans SM, Kachur AV, Shiue CY, Hustinx R, Jenkins WT, Shive GG, et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. JNucl Med 2000; 4l (2): 327–336.

    Google Scholar 

  161. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998; 46 (3): 229–237.

    Article  PubMed  CAS  Google Scholar 

  162. Thrall DE, Rosner GL, Azuma C, McEntee MC, Raleigh JA. Hypoxia marker labeling in tumor biopsies: quantification of labeling variation and criteria for biopsy sectioning. Radiother Oncol 1997; 44 (2): 171–176.

    Article  PubMed  CAS  Google Scholar 

  163. Raleigh JA, Zeman EM, Calkins DP, McEntee MC, Thrall DE. Distribution of hypoxia and proliferation associated markers in spontaneous canine tumors. Acta Oncol 1995; 34 (3): 345–349.

    Article  PubMed  CAS  Google Scholar 

  164. Zeman EM, Calkins DP, Cline JM, Thrall DE, Raleigh JA. The relationship between proliferative and oxygenation status in spontaneous canine tumors. Int J Radiat Oncol Biol Phys 1993; 27 (4): 891–898.

    Article  PubMed  CAS  Google Scholar 

  165. Azuma C, Raleigh JA, Thrall DE. Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime. Radiat Res 1997; 148 (1): 35–42.

    Article  PubMed  CAS  Google Scholar 

  166. Vaupel P, Jain R. Tumor Blood Supply and Metabolic Microenvironment. Gustav Fischer Verlag Stuttgart, 1991

    Google Scholar 

  167. Prescott DM, Charles HC, Sostman HD, Dodge RK, Thrall DE, Page RL, et al. Therapy monitoring in human and canine soft tissue sarcomas using magnetic resonance imaging and spectroscopy. Int J Radiat Oncol Biol Phys 1994; 28 (2): 415–423.

    Article  PubMed  CAS  Google Scholar 

  168. Sostman HD, Prescott DM, Dewhirst MW, Dodge RK, Thrall DE, Page RL, et al. MR imaging and spectroscopy for prognostic evaluation in soft-tissue sarcomas. Radiology 1994; 190 (1): 269–275.

    PubMed  CAS  Google Scholar 

  169. Vujaskovic Z, Poulson J, Gaskin A, Thrall D, Page R, Charles H, et al. Temperature dependent changes in physiologic parameters of spontaneous canine soft tissue sarcomas after combined radiotherapy and hyperthermia. Int J Radiat Oncol Biol Phys 2000; 46: 179–185.

    Article  PubMed  CAS  Google Scholar 

  170. Engin K, Leeper D, Thistlethwaite A, Tupchong L, McFarlane J. Tumor extracellular pH as a prognostic factor in thermoradiotherapy. Int J Radiat Oncol Biol Phys 1994; 29: 125–132.

    Article  PubMed  CAS  Google Scholar 

  171. Walenta S, Salameh A, Lyng H, Evensen JF, Mitze M, Rofstad EK, et al. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Pathol 1997; 150 (2): 409–415.

    PubMed  CAS  Google Scholar 

  172. Schwickert G, Walenta S, Sundfor K, Rofstad E, Mueller-Klieser W. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res 1995; 55: 4757–4759.

    PubMed  CAS  Google Scholar 

  173. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 1996; 56 (6): 1194–1198.

    PubMed  CAS  Google Scholar 

  174. Prescott DM, Charles HC, Poulson JM, Page RL, Thrall DE, Vujaskovic Z, et al. The relationship between intracellular and extracellular pH in spontaneous canine tumors [In Process Citation]. Clin Cancer Res 2000; 6 (6): 2501–2505.

    PubMed  CAS  Google Scholar 

  175. Voorhees WDd, Babbs CF. Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs. Eur J Cancer Clin Oncol 1982; 18 (10): 1027–1033.

    Article  Google Scholar 

  176. Babbs CF, DeWitt DP, Voorhees WD, McCaw JS, Chan RC. Theoretical feasibility of vasodilator-enhanced local tumor heating. Eur J Cancer Clin Oncol 1982; 18 (11): 1137–1146.

    Article  PubMed  CAS  Google Scholar 

  177. Dewhirst MW, Prescott DM, Clegg S, Samulski TV, Page RL, Thrall DE, et al. The use of hydralazine to manipulate tumour temperatures during hyperthermia. Int J Hyperthermia 1990; 6 (6): 971–983.

    Article  PubMed  CAS  Google Scholar 

  178. Prescott DM, Samulski TV, Dewhirst MW, Page RL, Thrall DE, Dodge RK, et al. Use of nitroprusside to increase tissue temperature during local hyperthermia in normal and tumor-bearing dogs. Int J Radiat Oncol Biol Phys 1992; 23 (2): 377–385.

    Article  PubMed  CAS  Google Scholar 

  179. Poulson J, Dewhirst M, Gaskin A, Samulski T, Prescott D, Meyer R, et al. Unexpected toxicity associated with nitric oxide synthase inhibition in tumor-bearing dogs. In Vivo 2000; 14: 709–714.

    PubMed  CAS  Google Scholar 

  180. Kilbourn R, Szabo, C, Traber, DL. Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: Lessons learned from experimental and clinical studies. Shock 1997; 7: 235–246.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Mark W. Dewhirst DVM, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald Thrall DVM, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Gregory MacEwen DVM
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lilly Research Laboratories, Indianapolis, IN, USA

    Beverly A. Teicher

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Dewhirst, M.W., Thrall, D., MacEwen, E.G. (2002). Spontaneous Pet Animal Cancers. In: Teicher, B.A. (eds) Tumor Models in Cancer Research. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-100-8_30

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-100-8_30

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6883-1

  • Online ISBN: 978-1-59259-100-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation